Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 756289, 8 pages
http://dx.doi.org/10.1155/2010/756289
Review Article

Iron Chelation Therapy in Myelodysplastic Syndromes

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Regione Gonzole 10, 10043 Orbassano (To), Italy

Received 1 October 2009; Revised 18 January 2010; Accepted 20 April 2010

Academic Editor: Jeffery Lynn Miller

Copyright © 2010 Emanuela Messa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Aul, D. T. Bowen, and Y. Yoshida, “Pathogenesis, etiology and epidemiology of myelodysplastic syndromes,” Haematologica, vol. 83, no. 1, pp. 71–86, 1998. View at Google Scholar · View at Scopus
  2. P. Greenberg, C. Cox, and C. Cox, “International scoring system for evaluating prognosis in myelodysplastic syndromes,” Blood, vol. 89, no. 6, pp. 2079–2088, 1997. View at Google Scholar · View at Scopus
  3. A. F. List, “Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes,” Cancer Control, vol. 15, no. 4, pp. 29–39, 2008. View at Google Scholar · View at Scopus
  4. M. Cazzola and L. Malcovati, “Myelodysplastic syndromes—coping with ineffective hematopoiesis,” The New England Journal of Medicine, vol. 352, no. 6, pp. 536–538, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. Malcovati, M. G. Della Porta, and M. Cazzola, “Predicting survival and leukemic evolution in patients with myelodysplastic syndrome,” Haematologica, vol. 91, no. 12, pp. 1588–1590, 2006. View at Google Scholar · View at Scopus
  6. Z. I. Cabantchik, W. Breuer, G. Zanninelli, and P. Cianciulli, “LPI-labile plasma iron in iron overload,” Best Practice and Research: Clinical Haematology, vol. 18, no. 2, pp. 277–287, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. A. Leitch, C. S. Leger, T. A. Goodman et al., “Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy,” Clinical Leukemia, vol. 2, pp. 205–211, 2008. View at Google Scholar
  8. C. Rose, S. Brechignac, D. Vassilief et al., “Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM,” Blood, vol. 110, article 249a, 2007. View at Google Scholar
  9. G. Sanz, B. Nomdedeu, E. Such et al., “Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome,” Blood, vol. 112, article 640a, 2008. View at Google Scholar
  10. P. Armand, H. T. Kim, and H. T. Kim, “Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation,” Blood, vol. 109, no. 10, pp. 4586–4588, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. V. Pullarkat, S. Blanchard, B. Tegtmeier, A. Dagis, K. Patane, J. Ito, and S. J. Forman, “Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 42, no. 12, pp. 799–805, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. V. Pullarkat, “Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?” Blood, vol. 114, no. 26, pp. 5251–5255, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. N. Gattermann, “Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload,” Leukemia Research, vol. 31, no. 3, pp. S10–S15, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. E. P. Alessandrino, S. Amadori, and S. Amadori, “Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the italian society of hematology,” Haematologica, vol. 87, no. 12, pp. 1286–1306, 2002. View at Google Scholar · View at Scopus
  15. D. Bowen, D. Culligan, S. Jowitt, S. Kelsey, G. Mufti, D. Oscier, and J. Parker, “Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes,” British Journal of Haematology, vol. 120, no. 2, pp. 187–200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. National Comprehensive Cancer Network, “NCCN Clinical Practice Guidelines. Myelodysplastic Syndromes,” 2009, http://www.nccn.org/.
  17. T. Suzuki, M. Tomonaga, and M. Tomonaga, “Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes,” International Journal of Hematology, vol. 88, no. 1, pp. 30–35, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. M. Bennett, “Consensus statement on iron overload in myelodysplastic syndromes,” American Journal of Hematology, vol. 83, no. 11, pp. 858–861, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. A. Wells, B. Leber, and B. Leber, “Iron overload in myelodysplastic syndromes: a Canadian consensus guideline,” Leukemia Research, vol. 32, no. 9, pp. 1338–1353, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. P. Valent, O. Krieger, and O. Krieger, “Iron overload in myelodysplastic syndromes (MDS)—diagnosis, management, and response criteria: a proposal of the Austrian MDS platform,” European Journal of Clinical Investigation, vol. 38, no. 3, pp. 143–149, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Mittelman, G. Lugassy, D. Merkel, H. Tamary, N. Sarid, E. Rachmilewitz, and C. Hershko, “Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines,” Israel Medical Association Journal, vol. 10, no. 5, pp. 374–376, 2008. View at Google Scholar · View at Scopus
  22. M. Kruszewski, “The role of labile iron pool in cardiovascular diseases,” Acta Biochimica Polonica, vol. 51, no. 2, pp. 471–480, 2004. View at Google Scholar · View at Scopus
  23. A. I. Schafer, R. G. Cheron, R. Dluhy et al., “Clinical consequences of acquired transfusional iron overload in adults,” The New England Journal of Medicine, vol. 304, no. 6, pp. 319–324, 1981. View at Google Scholar · View at Scopus
  24. L. M. Buja and W. C. Roberts, “Iron in the heart. Etiology and clinical significance,” The American Journal of Medicine, vol. 51, no. 2, pp. 209–221, 1971. View at Google Scholar · View at Scopus
  25. P. Mathew, A. Tefferi, G. W. Dewald, S. L. Goldberg, J. Su, H. C. Hoagland, and P. Noel, “The 5q-syndrome: a single-institution study of 43 consecutive patients,” Blood, vol. 81, no. 4, pp. 1040–1045, 1993. View at Google Scholar · View at Scopus
  26. L. Malcovati, M. G. Della Porta, and M. G. Della Porta, “Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7594–7603, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. L. Malcovati, “Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes,” Leukemia Research, vol. 31, supplement 3, pp. S2–S6, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. L. Malcovati, U. Germing, and U. Germing, “Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3503–3510, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Cermak, P. Kacirkova, D. Mikulenkova, and K. Michalova, “Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts,” Leukemia Research, vol. 33, no. 11, pp. 1469–1474, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. Takatoku, T. Uchiyama, S. Okamoto et al., “Retrospective nationwide survey of Japanese patients with transfusiondependent MDS and aplastic anemia highlights the negative impact of iron overload onMorbiddity/mortality,” European Journal of Haematology, vol. 78, pp. 487–494, 2007. View at Google Scholar
  31. K. Naka, T. Muraguchi, T. Hosh II, and A. Hirao, “Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells,” Antioxidants and Redox Signaling, vol. 10, no. 11, pp. 1883–1894, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Koptyra, R. Falinski, and R. Falinski, “BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance,” Blood, vol. 108, no. 1, pp. 319–327, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. F. V. Rassool, T. J. Gaymes, and T. J. Gaymes, “Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?” Cancer Research, vol. 67, no. 18, pp. 8762–8771, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. C. E. Chee, D. P. Steensma, W. Wu, C. A. Hanson, and A. Tefferi, “Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts,” American Journal of Hematology, vol. 83, no. 8, pp. 611–613, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. M. G. Zurlo, P. De Stefano, and P. De Stefano, “Survival and causes of death in thalassaemia major,” Lancet, vol. 2, no. 8653, pp. 27–30, 1989. View at Google Scholar · View at Scopus
  36. L. M. Buja and W. C. Roberts, “Iron in the heart. Etiology and clinical significance,” The American Journal of Medicine, vol. 51, no. 2, pp. 209–221, 1971. View at Google Scholar · View at Scopus
  37. E. Konen, H. Ghoti, O. Goitein, A. Winder, T. Kushnir, Y. Eshet, and E. Rachmilewitz, “No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique,” American Journal of Hematology, vol. 82, no. 11, pp. 1013–1016, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. A. A. Di Tucci, G. Matta, and G. Matta, “Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias,” Haematologica, vol. 93, no. 9, pp. 1385–1388, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. Chacko, D. J. Pennell, and D. J. Pennell, “Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions,” British Journal of Haematology, vol. 138, no. 5, pp. 587–593, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. D. Jensen, F. T. Jensen, T. Christensen, H. Eiskjaer, U. Baandrup, and J. L. Nielsen, “Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferioxamine: indication of close relation between myocardial iron content and chelatable iron pool,” Blood, vol. 101, pp. 4632–4639, 2003. View at Google Scholar
  41. J. J. Bullen, H. J. Rogers, P. B. Spalding, and C. G. Ward, “Natural resistance, iron and infection: a challenge for clinical medicine,” Journal of Medical Microbiology, vol. 55, no. 3, pp. 251–258, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. D. P. Kontoyiannis, G. Chamilos, and G. Chamilos, “Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation,” Cancer, vol. 110, no. 6, pp. 1303–1306, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. A. Altes, A. F. Remacha, and A. F. Remacha, “Early clinical impact of iron overload in stem cell transplantation. A prospective study,” Annals of Hematology, vol. 86, no. 6, pp. 443–447, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. R. Boelaert, M. De Locht, and M. De Locht, “Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies,” Journal of Clinical Investigation, vol. 91, no. 5, pp. 1979–1986, 1993. View at Google Scholar · View at Scopus
  45. A. S. Ibrahim, T. Gebermariam, and T. Gebermariam, “The iron chelator deferasirox protects mice from mucormycosis through iron starvation,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2649–2657, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. A. Mahindra, R. Sobecks, L. Rybicki et al., “Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogenic hematopoietic stem cell transplantation,” British Journal of Haematology, vol. 146, pp. 310–316, 2009. View at Google Scholar
  47. W. Y. Au, W. M. Lam, and W. M. Lam, “A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels,” Transplantation Proceedings, vol. 39, no. 10, pp. 3369–3374, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. T. de Witte, “The role of iron in patients after bone marrow transplantation,” Blood Reviews, vol. 22, no. 2, pp. S22–S28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. L. von Bonsdorff, L. Sahlstedt, F. Ebeling, T. Ruutu, and J. Parkkinen, “Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron,” FEMS Immunology and Medical Microbiology, vol. 37, no. 1, pp. 45–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Borgna-Pignatti, S. Rugolotto, and S. Rugolotto, “Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine,” Haematologica, vol. 89, no. 10, pp. 1187–1193, 2004. View at Google Scholar · View at Scopus
  51. V. Gabutti and A. Piga, “Results of long-term iron-chelating therapy,” Acta Haematologica, vol. 95, no. 1, pp. 26–36, 1996. View at Google Scholar · View at Scopus
  52. E. J. Neufeld, “Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions,” Blood, vol. 107, no. 9, pp. 3436–3441, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. M. D. Cappellini and P. Pattoneri, “Oral iron chelators,” Annual Review of Medicine, vol. 60, pp. 25–38, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. G. J. Kontoghiorghes, K. Pattichi, M. Hadjigavriel, and A. Kolnagou, “Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1),” Transfusion Science, vol. 23, no. 3, pp. 211–223, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. M. D. Cappellini, “Long-term efficacy and safety of deferasirox,” Blood Reviews, vol. 22, no. 2, pp. S35–S41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. M. D. Cappelini, A. Choen, A. Piga et al., “A phase 3 study of deferasirox (ICL670), a once-daily oral chelator, in patients with-thalassemia,” Blood, vol. 107, pp. 3455–3462, 2006. View at Google Scholar
  57. A. Piga, R. Galanello, and R. Galanello, “Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload,” Haematologica, vol. 91, no. 7, pp. 873–880, 2006. View at Google Scholar · View at Scopus
  58. E. Vichinsky, O. Onyekwere, and O. Onyekwere, “A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease,” British Journal of Haematology, vol. 136, no. 3, pp. 501–508, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. J. Porter, R. Galanello, and R. Galanello, “Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study,” European Journal of Haematology, vol. 80, no. 2, pp. 168–176, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. N. Gattermann, M. Schmid, M. Della Porta et al., “Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial,” Blood, vol. 112, article 633a, 2008. View at Google Scholar
  61. H. A. Leitch and L. M. Vickars, “Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?” Hematology, pp. 664–672, 2009. View at Google Scholar · View at Scopus
  62. P. D. Jensen, I. M. Jensen, and J. Ellegaard, “Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome,” British Journal of Haematology, vol. 80, no. 1, pp. 121–124, 1992. View at Google Scholar · View at Scopus
  63. P. D. Jensen, L. Heickendorff, and L. Heickendorff, “The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload,” British Journal of Haematology, vol. 94, no. 2, pp. 288–299, 1996. View at Google Scholar · View at Scopus
  64. M. E. P. Smeets, S. Vreugdenhil, and R. S. G. Holdrinet, “Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis,” American Journal of Hematology, vol. 51, no. 3, pp. 243–244, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. A. A. Di Tucci, R. Murru, D. Alberti, B. Rabault, S. Deplano, and E. Angelucci, “Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670),” European Journal of Haematology, vol. 78, no. 6, pp. 540–542, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. E. Messa, D. Cilloni, F. Messa, F. Arruga, A. Roetto, and G. Saglio, “Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis,” Acta Haematologica, vol. 120, no. 2, pp. 70–74, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. S. Capalbo, G. Spinosa, M. G. Franzese, and G. Palumbo, “Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements,” Acta Haematologica, vol. 121, no. 1, pp. 19–20, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. F. List, M. R. Baer, D. Steensma et al., “Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS),” Blood, vol. 112, article 634a, 2008. View at Google Scholar
  69. C. Camaschella, A. Campanella, and A. Campanella, “The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload,” Blood, vol. 110, no. 4, pp. 1353–1358, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. J. Hartmann, U. Sinzig, G. Wulf et al., “Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS,” Blood, vol. 112, article 2694a, 2008. View at Google Scholar
  71. E. Messa, S. Carturan, C. Maffè et al., “Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging,” Haematologica. In press.
  72. D. P. Steensma, “Myelodysplasia paranoia: iron as the new radon,” Leukemia Research, vol. 33, no. 9, pp. 1158–1163, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. A. Tefferi and R. M. Stone, “Iron chelation therapy in myelodysplastic syndrome—Cui bono?” Leukemia, vol. 23, no. 8, p. 1373, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus